Etanercept is a recombinant soluble tumour necrosis factor alpha receptor administered subcutaneously at the dose of 50 mg weekly (or 25 mg/twice weekly) for the treatment of the main chronic arthritides: rheumatoid arthritis and spondyloarthropathies. It shows high qualities in terms of efficacy and manageability. Favourable results were reported in all localisations of spondyloarthropathies: axial disease, peripheral arthritis, and enthesitis. In particular, several studies demonstrated its efficacy on the clinical and functional indicators of ankylosing spondylitis. Similar data were also reported for psoriatic arthritis in which, in addition, a significant reduction in the progression of erosive damages was widely described. Furthermore, although only a few studies are available, very interesting results have been obtained in patients suffering from undifferentiated spondyloarthropathies and severe enthesitis.

Etanercept in spondyloarthropathies. Part I: current evidence of efficacy / Palazzi, Carlo; D'Angelo, Salvatore; Cantini, Fabrizio; Lubrano, Ennio; Marchesoni, Antonio; Mathieu, Alessandro; Salvarani, Carlo; Scarpa, Raffaele; Spadaro, Antonio; Olivieri, Ignazio. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - 29:(2011), pp. 858-864.

Etanercept in spondyloarthropathies. Part I: current evidence of efficacy

SALVARANI, CARLO;
2011

Abstract

Etanercept is a recombinant soluble tumour necrosis factor alpha receptor administered subcutaneously at the dose of 50 mg weekly (or 25 mg/twice weekly) for the treatment of the main chronic arthritides: rheumatoid arthritis and spondyloarthropathies. It shows high qualities in terms of efficacy and manageability. Favourable results were reported in all localisations of spondyloarthropathies: axial disease, peripheral arthritis, and enthesitis. In particular, several studies demonstrated its efficacy on the clinical and functional indicators of ankylosing spondylitis. Similar data were also reported for psoriatic arthritis in which, in addition, a significant reduction in the progression of erosive damages was widely described. Furthermore, although only a few studies are available, very interesting results have been obtained in patients suffering from undifferentiated spondyloarthropathies and severe enthesitis.
2011
29
858
864
Etanercept in spondyloarthropathies. Part I: current evidence of efficacy / Palazzi, Carlo; D'Angelo, Salvatore; Cantini, Fabrizio; Lubrano, Ennio; Marchesoni, Antonio; Mathieu, Alessandro; Salvarani, Carlo; Scarpa, Raffaele; Spadaro, Antonio; Olivieri, Ignazio. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - 29:(2011), pp. 858-864.
Palazzi, Carlo; D'Angelo, Salvatore; Cantini, Fabrizio; Lubrano, Ennio; Marchesoni, Antonio; Mathieu, Alessandro; Salvarani, Carlo; Scarpa, Raffaele; Spadaro, Antonio; Olivieri, Ignazio
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1078923
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 16
social impact